A phase 1 trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer

PURPOSE: This trial was conducted to determine the maximum tolerated dose (MTD) and preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in postmenopausal women with metastatic estrogen receptor positive breast cancer (ER+BC). EXPERIMENTAL DESIGN: Phase IA employe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Ma, Cynthia X., Luo, Jingqin, Naughton, Michael, Ademuyiwa, Foluso, Suresh, Rama, Griffith, Malachi, Griffith, Obi L., Skidmore, Zachary L., Spies, Nicholas C., Ramu, Avinash, Trani, Lee, Pluard, Timothy, Nagaraj, Gayathri, Thomas, Shana, Guo, Zhanfang, Hoog, Jeremy, Han, Jing, Mardis, Elaine, Lockhart, Craig, Ellis, Matthew J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4818722/
https://ncbi.nlm.nih.gov/pubmed/26563128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1745
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados